Dapagliflozin Clinical Evidence and Guidelines

Established Clinical Evidence

The American Diabetes Association recommends dapagliflozin for glycemic control in type 2 diabetes, based on evidence from multiple large cardiovascular outcomes trials (CVOTs), including the DECLARE-TIMI 58 trial and the DAPA-HF trial 1, 2
Dapagliflozin has accumulated substantial evidence supporting its use in cardiovascular risk reduction, with studies demonstrating its effectiveness in reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure 3, 2
The American College of Cardiology recommends dapagliflozin for heart failure management, citing its ability to reduce the risk of hospitalization for heart failure and cardiovascular death in adults with heart failure 3, 1
Dapagliflozin has also demonstrated renal protective effects, reducing the risk of sustained eGFR decline and end-stage kidney disease in adults with chronic kidney disease at risk of progression 4, 5

The American Association of Clinical Endocrinologists recommends dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, with a standard dosing of 5 mg once daily, potentially increasing to 10 mg once daily 4
Dapagliflozin is commonly used in combination with other antidiabetic medications, such as metformin, sitagliptin, and insulin, and has a well-characterized safety profile with common side effects including increased risk of genital mycotic infections and urinary tract infections 6, 3

The European Medicines Agency recommends caution when using dapagliflozin in patients with renal impairment, as it is not recommended for glycemic control if eGFR <45 mL/min/1.73m², and has a low risk of hypoglycemia when used as monotherapy 6

The American College of Cardiology recommends that dapagliflozina has a very low intrinsic risk of hypoglycemia when used as monotherapy or in combination with metformin, due to its mechanism of action (inhibition of SGLT2 renal) being independent of insulin secretion 7
SGLT2 inhibitors, including dapagliflozina, do not increase the risk of hypoglycemia when used alone because they reduce glucose through urinary excretion rather than stimulating insulin release 7
In cardiovascular clinical trials such as DAPA-HF, severe hypoglycemia occurred in only 0.2-0.3% of patients treated with dapagliflozina versus placebo, demonstrating a favorable safety profile 8

The American College of Cardiology (2018) specifies that the risk of hypoglycemia increases with insulin and insulin secretagogues, requiring dose adjustment of these agents when dapagliflozina is added 9
The incidence of reported hypoglycemic events with dapagliflozina in clinical trials varies depending on the background therapy, being higher when combined with insulin or sulfonylureas 9, 10, 11, 12

When initiating dapagliflozina, if the patient is on insulin, reduce the insulin dose by 10-20% to prevent hypoglycemia 9, 12
If the patient is using sulfonylureas or other secretagogues, consider reducing the dose of the secretagogue or switching to an agent with a lower risk of hypoglycemia (such as DPP-4 inhibitors) 9, 12

The American Diabetes Association notes that meglitinides, such as repaglinide and nateglinide, have a similar risk of hypoglycemia as sulfonylureas when combined with dapagliflozin 13
The American College of Cardiology recommends reducing insulin dose by 10-20% when initiating dapagliflozin in patients on insulin therapy 14

The American College of Cardiology suggests that when patients are on complex insulin regimens, involving endocrinologists or primary care providers is essential to prevent hypoglycemia 14
The American College of Cardiology recommends that patients with HbA1c <8.5% on sulfonylureas should strongly consider stopping the sulfonylurea when initiating dapagliflozin 15

The American College of Cardiology states that patients without diabetes using dapagliflozin for heart failure or CKD do not have a concern for hypoglycemia 15